Výsledky vyhledávání

Plerixafor (Mozobil®) Alone to Mobilize Hematopoietic Stem Cells from Multiple Myeloma Patients for Autologous Transplantation

Autor: Neal Flomenberg, Karin Badel, Raymond L. Comenzo, Gary Calandra

Publikováno v: Biology of Blood and Marrow Transplantation. 16(5):695-700

Rapid and durable recovery of hematopoietic function after hematopoietic stem cell transplantation (HSCT) requires the infusion of a sufficient number of hematopoietic stem cells (HSC). Granulocyte colony-stimulating factor (G-CSF), either alone or w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f77138e41f2c1fede828456b1324c73b

Zobrazit plný text záznamu

A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment

Autor: Ronald Trevor Macfarland, Marjie L. Hard, Karin Badel, Gary Calandra, Robert J. Scarborough

Publikováno v: Biology of Blood and Marrow Transplantation. 16(1):95-101

Plerixafor is a selective antagonist of CXCR4 used for mobilization of hematopoietic stem cells (HSCs) for autologous stem cell transplantation (SCT) in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). This Phase 1 open-label study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39c7eadd3a888b9d447fbe9ec4489e41

Zobrazit plný text záznamu

A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma

Autor: Karin Badel, Ron MacFarland, Gary Calandra, John F. DiPersio, Feng Gao, Amanda F. Cashen, Sandra Lopez

Publikováno v: Biology of Blood and Marrow Transplantation. 14(11):1253-1261

Collection of an adequate number of hematopoietic stem cells can be difficult in patients with relapsed or refractory Hodgkin lymphoma (HL) who are candidates for autologous stem cell transplantation (ASCT). Plerixafor (AMD3100), an inhibitor of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e10703703bec9c62048a92cb9a91eb29

Zobrazit plný text záznamu

Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

Autor: Neal Flomenberg, Gary Calandra, David H. Vesole, Daniel J. Weisdorf, John F. DiPersio, Jane L. Liesveld, Steven M. Devine, Karin Badel

Publikováno v: Journal of Clinical Oncology. 22:1095-1102

Purpose Interactions between the chemokine receptor CXCR4 and its ligand stromal derived factor-1 regulate hematopoietic stem-cell trafficking. AMD3100 is a CXCR4 antagonist that induces rapid mobilization of CD34+ cells in healthy volunteers. We per

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06e9f5e2dfde096750be88ef2807d8e
https://doi.org/10.1200/jco.2004.07.131

Zobrazit plný text záznamu

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients

Autor: Gerhard Ehninger, S Müller, Julian Topaly, H. Goldschmidt, Stefan Fruehauf, A. D. Ho, Kai Hübel, G. Calandra, Marion Moos, Karin Badel

Publikováno v: Bone marrow transplantation. 45(2)

This report describes the first investigational use of plerixafor in Europe and the determination of tumor cell mobilization by polymerase chain-reaction after plerixafor treatment in a subset of patients with multiple myeloma (MM). Thirty-five patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9be2d5e35c2d8fe4e27621707222d94
https://pubmed.ncbi.nlm.nih.gov/19597422

Zobrazit plný text záznamu

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

Autor: C Dehner, A P Nademanee, Karin Badel, C Gibney, Gary Bridger, Richard T. Maziarz, Jane L. Liesveld, G. Calandra, Michael J. Dugan, William I. Bensinger

Publikováno v: Bone marrow transplantation. 45(1)

Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfb2366c12e49be94525fb627df5f5ec
https://pubmed.ncbi.nlm.nih.gov/19483760

Zobrazit plný text záznamu

AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data

Autor: G. Calandra, Dye A, Joseph McGuirk, Guido Tricot, John M. McCarty, S.-A. Crocker, Grove B, Gary Bridger, Karin Badel

Publikováno v: Bone marrow transplantation. 41(4)

AMD3100 given with G-CSF has been shown to mobilize CD34+ cells in non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), and Hodgkin's disease (HD) patients who could not collect sufficient cells for autologous transplant following other mobilization

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098da103565e0c57c51bce95ed8ee008
https://pubmed.ncbi.nlm.nih.gov/17994119

Zobrazit plný text záznamu

Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients

Autor: Karin Badel, Cesar O. Freytes, Cagla Akay, Gary Calandra, Yair Gazitt

Publikováno v: Stem cells and development. 16(4)

AMD3100 is a drug capable of mobilizing peripheral blood stem cells (PBSCs) in donors and in cancer patients as a single agent or in combination with granulocyte-colony-stimulating factor (G-CSF). We initiated a phase II study of 11 refractory or rel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c84125d0642ef639978abe5429fb9208
https://pubmed.ncbi.nlm.nih.gov/17784839

Zobrazit plný text záznamu

The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone

Autor: Karin Badel, Jane L. Liesveld, John M. McCarty, Scott D. Rowley, Neal Flomenberg, Gary Calandra, David H. Vesole, Steven M. Devine, John F. DiPersio

Publikováno v: Blood. 106(5)

Hematopoietic progenitor cells (HPCs) traffic to and are retained in the marrow through the trophic effects of the chemokine stromal cell-derived factor-1alpha (SDF-1alpha) binding to its receptor, CXC chemokine receptor 4 (CXCR4). AMD3100 reversibly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e5ca0b9fb72e06535ca347df126b69
https://pubmed.ncbi.nlm.nih.gov/15890685

Zobrazit plný text záznamu

Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist

Autor: Jeffrey Christensen, David C. Dale, Christine Dehner, Brent L. Wood, Elin Rodger, Gary Calandra, Karin Badel, Thomas H. Price, Hal E. Broxmeyer, W. Conrad Liles

Publikováno v: Transfusion. 45(3)

BACKGROUND: AMD3100, a selective antagonist of CXCR4, rapidly mobilizes CD34+ hematopoietic progenitor cells (HPCs) from marrow to peripheral blood with minimal side effects. STUDY DESIGN AND METHODS: To further investigate potential clinical utility

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f817054b89324da1bb4219a60a33ab
https://pubmed.ncbi.nlm.nih.gov/15752146

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání